Lizak lozenges with orange flavor №10×1

Name:
Lizak. Forms of release Tablets. FTH Anti-inflammatory agent for topical use. Composition 1 tablet contains: active ingredients: lysozyme hydrochloride 10 mg, dequalinium chloride 0.25 mg; excipients: for tablets with anise and mint flavor: lactose monohydrate; mannitol (E 421); povidone; magnesium stearate; flavorings: anise and mint; for tablets with chocolate flavor: dextrose monohydrate ST; povidone; magnesium stearate; flavoring additives: cocoa powder, chocolate; for tablets with orange flavor: dextrose monohydrate ST; povidone; magnesium stearate; flavor additive: orange; dyes: iron oxide yellow (E 172), iron oxide red (E 172); for raspberry flavored tablets: dextrose monohydrate ST; povidone; magnesium stearate; flavorings: with the smell of raspberries, with the smell of natural raspberries; dye: iron oxide red (E 172).
Description:
Tablets of white or almost white color, with a flat surface, notch and chamfer, with anise and mint flavor. Tablets from gray to brown, interspersed, with a flat surface, scored and chamfered, with a cocoa flavor. Marbling is allowed on the surface of the tablets. Tablets are pink-orange, interspersed, with a flat surface, notch and chamfer, with an orange flavor. Marbling is allowed on the surface of the tablets. Pink color tablets with a reddish tint, interspersed, with a flat surface, scored and chamfered, with a raspberry flavor. Pharmacotherapeutic groupMeans for the treatment of diseases of the larynx and pharynx. Antiseptics. Code ATX R02A A20. Pharmacological properties Pharmacodynamics. Lizak® is a combined preparation with a well-pronounced local antiseptic, antibacterial and antifungal action. The therapeutic effect of the drug is due to its constituent components. Dequalinium chloride – a local antiseptic of the quinoline group, has an antiseptic effect – mainly local; antibacterial action – mainly relative to gram-positive and gram-negative microorganisms; antifungal activity – mainly against Candida albicans, some species of Trychophyton and epidermophytes. The antibacterial effect is due to the denaturation of proteins and enzymes of the pathogen by dissolution and depolymerization, as well as glycolysis and inactivation of dehydrogenases; violation of protein synthesis at the level of ribosomes; cell membrane cytolysis. The surface-active cationic action underlies its bacteriostatic activity, which is stronger against gram-positive than gram-negative microorganisms. Lysozyme is an antibacterial agent, an enzyme of the hydrolase class that destroys the cell walls of bacteria by hydrolyzing the peptidoglycan of the bacterial cell wall. It is also effective against Gram-negative bacteria, viruses and fungi. Pharmacokinetics. Dequalinium chloride is absorbed in very small amounts. Lysozyme is well absorbed from the gastrointestinal tract. The peak concentration of lysozyme in the blood is reached after 1-1.5 hours. Lysozyme is widely distributed in the tissues of the body, especially accumulates in the mucous membranes. Hydrolyzed by intestinal enzymes, excreted in the form of metabolites in the urine. Indications for use Symptomatic treatment of infectious and inflammatory processes of the oral cavity and pharynx (as part of complex therapy): – acute pharyngitis; – exacerbation of chronic tonsillitis; – aphthous stomatitis; – candidiasis of the oral cavity and pharynx. Method of application and dosageRecommended doses for adults and children over 12 years of age. Apply 1 tablet for resorption every 2-3 hours (no more than 10 tablets per day). After reducing the symptoms of inflammation – 1 tablet every 4 hours. Recommended doses for children aged 6 to 12 years. Apply 1 tablet for resorption every 3 hours (no more than 5 tablets per day). After reducing the symptoms of inflammation – 1 tablet every 4 hours. The tablet should be sucked slowly, without chewing. After taking the drug, it is recommended not to eat or drink for 30 minutes. Treatment is recommended to continue for another 1-2 days after the disappearance of the symptoms of the disease. It is recommended to use Lizak® until the symptoms of the disease disappear. If the symptoms do not disappear after 5-7 days of treatment, you should consult a doctor to determine further treatment tactics. Side effects The following adverse reactions are possible: from the gastrointestinal tract: nausea, vomiting, dry mouth, oral dysbacteriosis (with prolonged use in high doses), stomatitis, diarrhea, stomach discomfort, anorexia; from the skin and subcutaneous tissue: allergic reactions are possible, including urticaria, rash, itching, toxic epidermal necrolysis, Stevens-Johnson syndrome, angioedema; from the immune system: hypersensitivity reactions, anaphylactic reactions (including anaphylactic shock), anaphylactoid reactions. local reactions, including a burning sensation and irritation in the throat and oral mucosa. In rare cases, namely with abuse, ulcers and necrosis may occur. In case of any adverse reactions, you should stop using the drug and be sure to consult your doctor regarding further therapy. ContraindicationsHypersensitivity to the active ingredients or any of the excipients (including allergy to egg white). Allergy to quaternary ammonium compounds (for example, benzalkonium chloride). Overdose There are no data on overdose. Precautions Anise and mint flavored tablets do not contain sugar, so they can be used by patients with diabetes. 1 lozenge with chocolate, orange or raspberry flavor contains 0.05 XE, which must be taken into account for patients with diabetes. If symptoms persist for 5 days or more and/or are accompanied by fever, medical advice is required. In the presence of general clinical signs of a bacterial infection, systemic antibiotic therapy should be considered. If any side effects occur, the drug should be discontinued and contact your doctor. It is not recommended to take Lizak® for more than 10 days due to the risk of imbalance in the normal microflora of the oral cavity. The drug contains lysozyme, so if you have a history of allergy to egg protein, you should not start treatment without first consulting your doctor. Simultaneous use with other drugs for local treatment should be carried out with caution. Anise and mint flavored tablets contain lactose and should not be used in patients with rare hereditary problems of galactose intolerance, the lactase deficiency or glucose-galactose malabsorption syndrome. Children. Do not use in children under 6 years of age. Use during pregnancy or lactation Given the lack of scientific data, Lizak® should not be used during pregnancy and lactation. The ability to influence the reaction rate when driving vehicles or working with other mechanisms Lizak® does not affect the performance of work that requires increased attention (driving vehicles and working with moving mechanisms). Interaction with other drugs When used simultaneously with kayexalate (an agent for the treatment of hyperkalemia), there is a possibility of developing severe necrotic lesions of the skin and mucous membranes, especially the gastrointestinal tract. The antibacterial activity of dequalinium chloride is reduced by the simultaneous use of anionic detergents, such as toothpaste. The use of the drug should not be combined with taking cholinesterase inhibitors. Storage conditions and shelf life Store at a temperature not exceeding 25 °C. Keep out of the reach of children. Best before date. 2 years. Do not use the drug after the expiration date indicated on the package. Holiday conditions Without a prescription. Packing: 10 tablets in a blister of opaque polymer film (white pigmented) and printed lacquered aluminum foil with or without perforation. 1 blister (10 tablets each), together with instructions for medical use, is put into a pack of cardboard. Buy Lizak lozenges with orange flavor No. 10×1 Price for Lizak lozenges with orange flavor No. 10×1 Instructions for use for Lizak lozenges with orange flavor No.